Literature DB >> 33670242

Impact of [18F]FDG-PET and [18F]FLT-PET-Parameters in Patients with Suspected Relapse of Irradiated Lung Cancer.

Tine N Christensen1,2, Seppo W Langer3,4, Gitte Persson4,5, Klaus Richter Larsen6, Annemarie G Amtoft1, Sune H Keller1, Andreas Kjaer1,2, Barbara Malene Fischer1,4,7.   

Abstract

Radiation-induced changes may cause a non-malignant high 2-deoxy-2-[18F]fluoro-d-glucose (FDG)-uptake. The 3'-deoxy-3'-[18F]fluorothymidine (FLT)-PET/CT performs better in the differential diagnosis of inflammatory changes and lung lesions with a higher specificity than FDG-PET/CT. We investigated the association between post-radiotherapy FDG-PET-parameters, FLT-PET-parameters, and outcome. Sixty-one patients suspected for having a relapse after definitive radiotherapy for lung cancer were included. All the patients had FDG-PET/CT and FLT-PET/CT. FDG-PET- and FLT-PET-parameters were collected from within the irradiated high-dose volume (HDV) and from recurrent pulmonary lesions. For associations between PET-parameters and relapse status, respectively, the overall survival was analyzed. Thirty patients had a relapse, of these, 16 patients had a relapse within the HDV. FDG-SUVmax and FLT-SUVmax were higher in relapsed HDVs compared with non-relapsed HDVs (median FDG-SUVmax: 12.8 vs. 4.2; p < 0.001; median FLT-SUVmax 3.9 vs. 2.2; p < 0.001). A relapse within HDV had higher FDG-SUVpeak (median FDG-SUVpeak: 7.1 vs. 3.5; p = 0.014) and was larger (median metabolic tumor volume (MTV50%): 2.5 vs. 0.7; 0.014) than the relapsed lesions outside of HDV. The proliferative tumor volume (PTV50%) was prognostic for the overall survival (hazard ratio: 1.07 pr cm3 [1.01-1.13]; p = 0.014) in the univariate analysis, but not in the multivariate analysis. FDG-SUVmax and FLT-SUVmax may be helpful tools for differentiating the relapse from radiation-induced changes, however, they should not be used definitively for relapse detection.

Entities:  

Keywords:  FDG-PET/CT; FLT-PET/CT; MTV; PTV; SUVmax; lung cancer; prognosis; relapse diagnosis

Year:  2021        PMID: 33670242      PMCID: PMC7916960          DOI: 10.3390/diagnostics11020279

Source DB:  PubMed          Journal:  Diagnostics (Basel)        ISSN: 2075-4418


  37 in total

1.  Influence of PET reconstruction technique and matrix size on qualitative and quantitative assessment of lung lesions on [18F]-FDG-PET: A prospective study in 37 cancer patients.

Authors:  Georg Riegler; Georgios Karanikas; Ivo Rausch; Albert Hirtl; Karem El-Rabadi; Wolfgang Marik; Christopher Pivec; Michael Weber; Helmut Prosch; Marius Mayerhoefer
Journal:  Eur J Radiol       Date:  2017-02-20       Impact factor: 3.528

2.  Differentiation of tumor recurrence from radiation-induced pulmonary fibrosis after stereotactic ablative radiotherapy for lung cancer: characterization of 18F-FDG PET/CT findings.

Authors:  Naomi Nakajima; Yoshifumi Sugawara; Masaaki Kataoka; Yasushi Hamamoto; Takashi Ochi; Shinya Sakai; Tadaaki Takahashi; Makoto Kajihara; Norihiro Teramoto; Motohiro Yamashita; Teruhito Mochizuki
Journal:  Ann Nucl Med       Date:  2013-01-09       Impact factor: 2.668

3.  Residual ¹⁸F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control.

Authors:  Vikram Rao Bollineni; Joachim Widder; Jan Pruim; Johannes A Langendijk; Erwin M Wiegman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-03-13       Impact factor: 7.038

4.  Changes in (18)F-fluorothymidine and (18)F-fluorodeoxyglucose positron emission tomography imaging in patients with head and neck cancer treated with chemoradiotherapy.

Authors:  Hiroshi Hoshikawa; Terushige Mori; Takehito Kishino; Yuka Yamamoto; Ryuhei Inamoto; Kosuke Akiyama; Nozomu Mori; Yoshihiro Nishiyama
Journal:  Ann Nucl Med       Date:  2013-02-03       Impact factor: 2.668

5.  18F-FLT PET during radiotherapy or chemoradiotherapy in head and neck squamous cell carcinoma is an early predictor of outcome.

Authors:  Bianca A W Hoeben; Esther G C Troost; Paul N Span; Carla M L van Herpen; Johan Bussink; Wim J G Oyen; Johannes H A M Kaanders
Journal:  J Nucl Med       Date:  2013-01-23       Impact factor: 10.057

6.  18F-FLT PET/CT Adds Value to 18F-FDG PET/CT for Diagnosing Relapse After Definitive Radiotherapy in Patients with Lung Cancer: Results of a Prospective Clinical Trial.

Authors:  Tine Nøhr Christensen; Seppo W Langer; Gitte Persson; Klaus Richter Larsen; Annika Loft; Annemarie Gjelstrup Amtoft; Anne Kiil Berthelsen; Helle Hjorth Johannesen; Sune Høgild Keller; Andreas Kjaer; Barbara Malene Fischer
Journal:  J Nucl Med       Date:  2020-10-09       Impact factor: 10.057

7.  A Systematic Literature Review on Salvage Radiotherapy for Local or Regional Recurrence After Previous Stereotactic Body Radiotherapy for Lung Cancer.

Authors:  Yukinori Matsuo
Journal:  Technol Cancer Res Treat       Date:  2018-01-01

8.  FLT-PET-CT for the Detection of Disease Recurrence After Stereotactic Ablative Radiotherapy or Hyperfractionation for Thoracic Malignancy: A Prospective Pilot Study.

Authors:  Susan M Hiniker; Quaovi Sodji; Andrew Quon; Paulina M Gutkin; Natasha Arksey; Edward E Graves; Frederick T Chin; Peter G Maxim; Maximilian Diehn; Billy W Loo
Journal:  Front Oncol       Date:  2019-05-31       Impact factor: 6.244

9.  Pilot study assessing (18)F-fluorothymidine PET/CT in cervical and vaginal cancers before and after external beam radiation.

Authors:  Linda P Cho; Chun K Kim; Akila N Viswanathan
Journal:  Gynecol Oncol Rep       Date:  2015-11-02

10.  Response criteria in solid tumors (PERCIST/RECIST) and SUVmax in early-stage non-small cell lung cancer patients treated with stereotactic body radiotherapy.

Authors:  Cory Pierson; Taras Grinchak; Casey Sokolovic; Brandi Holland; Teresa Parent; Mark Bowling; Hyder Arastu; Paul Walker; Andrew Ju
Journal:  Radiat Oncol       Date:  2018-02-27       Impact factor: 3.481

View more
  1 in total

1.  Correction: Christensen et al. Impact of [18F]FDG-PET and [18F]FLT-PET-Parameters in Patients with Suspected Relapse of Irradiated Lung Cancer. Diagnostics 2021, 11, 279.

Authors:  Tine N Christensen; Seppo W Langer; Gitte Persson; Klaus Richter Larsen; Annemarie G Amtoft; Sune H Keller; Andreas Kjaer; Barbara Malene Fischer
Journal:  Diagnostics (Basel)       Date:  2022-07-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.